Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 3
2004 1
2006 2
2010 1
2011 1
2019 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic.
Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, Askoxylakis V, Kirpotin DB, Bloom T, Mino-Kenudson M, Marks JD, Zalutskaya A, Bshara W, Morrison C, Drummond DC. Kamoun W, et al. Among authors: pien c. Pharmaceutics. 2020 Oct 20;12(10):996. doi: 10.3390/pharmaceutics12100996. Pharmaceutics. 2020. PMID: 33092175 Free PMC article.
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.
Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC. Kamoun WS, et al. Among authors: pien c. Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5. Nat Biomed Eng. 2019. PMID: 30952988
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK. Sydor JR, et al. Among authors: pien cs. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17408-13. doi: 10.1073/pnas.0608372103. Epub 2006 Nov 7. Proc Natl Acad Sci U S A. 2006. PMID: 17090671 Free PMC article.
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Papandreou CN, et al. Among authors: pien cs. J Clin Oncol. 2004 Jun 1;22(11):2108-21. doi: 10.1200/JCO.2004.02.106. J Clin Oncol. 2004. PMID: 15169797 Clinical Trial.
Novel IKK inhibitors: beta-carbolines.
Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, Parent L, Pien C, Palombella V, Adams J. Castro AC, et al. Among authors: pien c. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22. doi: 10.1016/s0960-894x(03)00408-6. Bioorg Med Chem Lett. 2003. PMID: 12824047
Assays for proteasome inhibition.
Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES. Elliott PJ, et al. Among authors: pien cs. Methods Mol Med. 2003;85:163-72. doi: 10.1385/1-59259-380-1:163. Methods Mol Med. 2003. PMID: 12710207 Review. No abstract available.
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Orlowski RZ, et al. Among authors: pien cs. J Clin Oncol. 2002 Nov 15;20(22):4420-7. doi: 10.1200/JCO.2002.01.133. J Clin Oncol. 2002. PMID: 12431963 Clinical Trial.
14 results